EUCTR2020-000842-32-IT进行中（未招募）1 期
A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment - .
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Willing and able to provide written informed consent prior to performing study procedures
- •2) Aged = 18 years
- •3) SARS-CoV-2 infection confirmed by PCR = 4 days before randomization
- •4) Currently hospitalized with fever defined as temperature = 36.6 °C armpit, = 37.2 °C oral, = 37.8 °C rectal
- •5) SpO2 > 94% on room air at screening
- •6) Radiographic evidence of pulmonary infiltrates
- •7) Men and women of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 200
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 400
排除标准
- •1) Participation in any other clinical trial of an experimental agent treatment for COVID-19
- •2) Concurrent treatment with other agents with actual or possible direct acting antiviral activity against SARS-CoV-2 is prohibited < 24 hours prior to study drug dosing
- •3) Requiring mechanical ventilation at screening
- •4) ALT or AST > 5 x ULN
- •5) Creatinine clearance < 50 mL/min
- •6) Positive pregnancy test (Appendix 3)
- •7) Breastfeeding woman
- •8) Known hypersensitivity to the study drug, the metabolites, or formulation excipient
研究者
相似试验
招募中
3 期
A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734*) in Participants with Moderate COVID-19 Compared to Standard of Care TreatmentCOVID-19Corona10047438NL-OMON49717Gilead Sciences40
进行中（未招募）
1 期
This study will test a drug named remdesivir (GS-5734™) to evaluate the safety and effectiveness of the drug in treating patients with severe coronavirus disease 2019 (COVID-19).Coronavirus disease 2019 (COVID-19)MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-000841-15-NLGilead Sciences, Inc.6,000
进行中（未招募）
1 期
This study will test a drug named remdesivir (GS-5734™) to evaluate the safety and effectiveness of the drug in treating patients with severe coronavirus disease 2019 (COVID-19).EUCTR2020-000841-15-ESGilead Sciences, Inc.400
进行中（未招募）
1 期
This study will test a drug named remdesivir (GS-5734™) to evaluate the safety and effectiveness of the drug in treating patients with moderate coronavirus disease 2019 (COVID-19) compared to standard of care treatment.Coronavirus disease 2019 (COVID-19)MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-000842-32-GBGilead Sciences, Inc.1,600
进行中（未招募）
1 期
This study will test a drug named remdesivir (GS-5734™) to evaluate the safety and effectiveness of the drug in treating patients with moderate coronavirus disease 2019 (COVID-19) compared to standard of care treatment.Coronavirus disease 2019 (COVID-19)MedDRA version: 20.0Level: LLTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 100000004862EUCTR2020-000842-32-SEGilead Sciences, Inc.1,600